Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis delta in patients hospitalized in Spain (1997-2018).
Ramos-Rincon JM, Pinargote H, Ramos-Belinchón C, de Mendoza C, Aguilera A, Soriano V. Ramos-Rincon JM, et al. Among authors: ramos belinchon c. AIDS. 2021 Nov 15;35(14):2311-2318. doi: 10.1097/QAD.0000000000003024. AIDS. 2021. PMID: 34261094
Esophagogastric variceal bleeding as a debut of Caroli's syndrome.
Del Río Izquierdo J, Ramos Belinchón C, Bañares R, Carrión Martín L. Del Río Izquierdo J, et al. Among authors: ramos belinchon c. Rev Esp Enferm Dig. 2022 Nov;114(11):678. doi: 10.17235/reed.2022.8813/2022. Rev Esp Enferm Dig. 2022. PMID: 35485265 Free article.
Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease.
Ramos Belinchón C, Martínez-Lozano H, Serrano Moreno C, Hernández Castillo D, Lois Chicharro P, Ferreira Ocampo P, Marín-Jiménez I, Bretón Lesmes I, Menchén L. Ramos Belinchón C, et al. Rev Esp Enferm Dig. 2024 May 20. doi: 10.17235/reed.2024.10305/2024. Online ahead of print. Rev Esp Enferm Dig. 2024. PMID: 38767015 Free article.
Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease.
Martin-Cardona A, Horta D, Florez-Diez P, Vela M, Mesonero F, Ramos Belinchón C, García MJ, Masnou H, de la Peña-Negro L, Suarez Ferrer C, Casanova MJ, Durán MO, Peña E, Calvet X, Fernández-Prada SJ, González-Muñoza C, Piqueras M, Rodríguez-Lago I, Sainz E, Bas-Cutrina F, Mancediño Marcos N, Ojeda A, Orts B, Sicilia B, García AC, Domènech E, Esteve M; ENEIDA registry of GETECCU. Martin-Cardona A, et al. Among authors: ramos belinchon c. Dig Liver Dis. 2024 Mar;56(3):468-476. doi: 10.1016/j.dld.2023.09.004. Epub 2023 Sep 26. Dig Liver Dis. 2024. PMID: 37770282
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain.
Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Ramos-Rincon JM, et al. Among authors: ramos belinchon c. Aliment Pharmacol Ther. 2023 Mar;57(5):540-548. doi: 10.1111/apt.17280. Epub 2022 Nov 1. Aliment Pharmacol Ther. 2023. PMID: 36320189